Complete blood count-derived inflammatory markers and survival in patients with localized renal cell cancer treated with partial or radical nephrectomy: a retrospective single-tertiary-center study
Authors:
Open Access
- 8 February 2022
- journal article
- research article
- Published by IMR Press in Frontiers in Bioscience-Scholar
- Vol. 14 (1) , 5
Abstract
We aimed to compare the predictive value of different inflammatory markers in renal cell carcinoma (RCC). Four hundred ninety-five patients treated with nephrectomy for primary localized or locally advanced RCC between 2010 and 2018 were included in the retrospective analysis. The median follow-up for the entire cohort was 48 months. Based on the preoperative laboratory measurements, patients with higher neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic inflammatory response index (SIRI), systemic immune-inflammation index (SII), neutrophil/erythrocyte ratio (NER), derived neutrophil/lymphocyte ratio (dNLR), and lower lymphocyte/monocyte ratio (LMR) and hemoglobin/platelet ratio (HPR) had worse cancer-specific survival (CSS). In the multivariate analysis tumour stage, grade, age and high SIRI constituted independent factors predicting CSS. The model including SIRI values achieved C-index 0.903 (alternative multivariate models with SII and NLR 0.902 and 0.890, respectively). Age, tumour grade and high NER (or high SIRI/ SII in alternative models) were prognostic for overall survival. Markers of systemic inflammation might provide additional prognostic information (especially SIRI, SII, NLR and NER) and further increase the predictive accuracy of available models in localized and locally advanced renal cell carcinoma. For the first time, we show the prognostic value of neutrophil-to-erythrocyte ratio, which constitutes an independent risk factor of overall survival.Keywords
All Related Versions
This publication has 27 references indexed in Scilit:
- Prognostic Significance of Inflammation-associated Blood Cell Markers in Nonmetastatic Clear Cell Renal Cell CarcinomaClinical Genitourinary Cancer, 2020
- Systemic immune inflammation index is a promising non-invasive marker for the prognosis of the patients with localized renal cell carcinomaInternational Urology and Nephrology, 2020
- Prognostic value of preoperative NLR, dNLR, PLR and CRP in surgical renal cell carcinoma patientsWorld Journal of Urology, 2016
- Comparison of the prognostic value of pretreatment measurements of systemic inflammatory response in patients undergoing curative resection of clear cell renal cell carcinomaWorld Journal of Urology, 2015
- Low preoperative lymphocyte-monocyte ratio (LMR) represents a potentially poor prognostic factor in nonmetastatic clear cell renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2014
- Clinical management of renal cell carcinoma with venous tumor thrombusWorld Journal of Urology, 2014
- Thinking beyond surgery in the management of renal cell carcinoma: the risk to die from renal cell carcinoma and competing risks of deathWorld Journal of Urology, 2014
- Markers of systemic inflammation predict survival in patients with advanced renal cell cancerBritish Journal of Cancer, 2013
- Outcomes and Clinicopathologic Variables Associated With Late Recurrence After Nephrectomy for Localized Renal Cell CarcinomaUrology, 2011
- Evaluation of an inflammation‐based prognostic score in patients with metastatic renal cancerCancer, 2007